


Express Mail No. EV780368135US

Date of Deposit: March 30, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Guenther, Catherine	Examiner:	Wilson, Michael C.
Serial No.:	09/883,093	Group Art Unit:	1632
Filed:	June 14, 2001	Docket No.:	R126/75658.241
Confirmation No.:	7936		
Title:	Transgenic Mice Containing Nuclear Hormone Receptor Gene Disruptions		



INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Please charge any fees or credit any overpayment to Deposit Account No. **502775**.


In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided, unless previously submitted.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Respectfully submitted,

3-30-06
Date



JEB
John E. Burke, Reg. No. 35,836
Greenberg Traurig LLP
1200 17th Street, Suite 2400
Denver, CO 80202
303.685.7411
720.904.6111 (fax)



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: R126/75658.241	Application Number: 09/883,093
	Applicant: Guenther, Catherine	
	Filing Date: June 14, 2001	Group Art Unit: 1632

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Sands (Industrializing Breakthrough Discovery, Current Drug Discovery 2002); pp. 21-23				
		NIH Press Release, October 5, 2005 – Trans-NIH Effort Provides New Models for Understanding Human Disease				
		Wolfer et al., TRENDS in Neuroscience, 25:336-340, Knockout Mice: Simple Solutions To The Problem Of Genetic Background And Flanking Genes				
		Maglich, et al., Nuclear Pregnane X Receptor and Constitutive Androstane Receptor Regulate Overlapping but Distinct Sets of Genes Involved in Xenobiotic Detoxification, Mol. Pharmacol., 62(3): 638-646, 2002				
		Ueda, et al., Diverse Roles of the Nuclear Orphan Receptor CAR in Regulating Hepatic Genes in Response to Phenobarbital, Mol. Pharmacol. 61(1): 1-6, 2002				
		Huang, et al., Induction of Bilirubin Clearance by the Constitutive Androstane Receptor (CAR), PNAS, 100(7): 4156-4161, 2003				
		Zhang, et al., The Constitutive Androstane Receptor and Pregnane X Receptor Function Coordinately to Prevent Bile Acid-induced Hepatotoxicity, J. Biol. Chem., 279(47): 49517-49522, 2004				
		Maglich, et al., The Nuclear Receptor CAR is a Regulator of Thyroid Hormone Metabolism During Caloric Restriction, J. Biol. Chem., 279(19): 19832-19838, 2004				
		Huang, et al., A Traditional Herbal Medicine Enhances Bilirubin Clearance by Activating the Nuclear Receptor CAR, J. Clin. Invest., 113(1): 137-143, 2004				
		Huang, et al., Meclizine is an Agonist Ligand for Mouse Constitutive Androstane Receptor (CAR)(and an Inverse Agonist for Human CAR, Mol. Endocrinol., 18(10):2402-2408, 2004				

X = These documents have been previously submitted in parent application(s) and are not attached hereto.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	